The efficacy of COX-1 inhibitor combined with agatroban in the treatment of patients with pro-gressive acute cerebral infarction and its impact on serum LPA and GFAP levels
The efficacy of COX-1 inhibitor combined with agatroban in the treatment of patients with pro-gressive acute cerebral infarction and its impact on serum LPA and GFAP levels
Objective To investigate the effects of agattroban combined with COX-1 inhibitor(aspirin)on neurological function score,living ability index score and serum lysophosphatidic acid(LPA)and glial fibrillary acidic protein(GFAP)levels in patients with acute progressive cerebral infarction.Methods Eighty patients with acute progressive cerebral in-farction diagnosed and treated in Neurology Department of our hospital from June 2019 to June 2021 were prospectively se-lected.Patients were randomly classified into two groups via numeral grouping methods,each with 40 cases.Control group received aspirin,based on this,treatment group received agattroban.Then comparison was conducted on clinical efficacy,National Institutes of Health Stroke Scale(NIHSS)score,Barthel Index,serum levels of LPA、GFAP and adverse reactions.Results Compared with control group,treatment group achieved higher clinical efficacy rate(95％),with statistical differ-ence(P＜0.05).Baseline NIHSS and Barthel index yielded no statistical difference between two groups(P＞0.05).At post-treatment 14d,a decrease in NIHSS score along with an increase in Barthel index were observed in both groups,and treatment group scored lower on NIHSS(25.47±4.02)and higher on Barthel Index(52.99±6.03)than those of control group(P＜0.05).Serum levels of LPA and GFAP demonstrated no significant difference between two groups before treat-ment(P＞0.05),while a decrease in LPA level and an increase in GFAP were found in both groups at post-treatment 14d(P＜0.05),and treatment group had lower LPA(1.28±0.21)u/L and higher GFAP(4.98±0.99)pg/ml levels than those of control group(P＜0.05).At post-treatment 14d,20.00％of adverse reactions in the treatment group were signifi-cantly lower than 47.50％in the control group(P＜0.05).Conclusion Application of agattroban combined with COX-1 inhibitor aspirin in the treatment of acute progressive cerebral infarction can effectively reduce the serum levels of LPA and GFAP,reduce adverse reaction rate and ameliorate the neurological function and activity of daily living,which is worthy of recommendation.
维普
万方数据